Healthcare provider profile · identity verified

Hani H Hashem, MD

Allopathic & Osteopathic Physicians|Internal Medicine · COVINA, CA · NPI 1033179379

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Hani H Hashem, MD received $177.33 in general payments during 2025 across 2 reported records.

ABBVIE INC. accounted for 70.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$177.33

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$124.99	70.5%	1	2025
Edwards Lifesciences Corporation	Unresolved — no canonical attribution shown	$52.34	29.5%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$177.33	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
RINVOQ Normalized: rinvoq	Biological	ABBVIE INC.	$124.99	1	2025
Source payment records 2025-02-05 · ABBVIE INC. · $124.99 · Open Payments source
SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia	Device	Edwards Lifesciences Corporation	$52.34	1	2025
Source payment records 2025-09-10 · Edwards Lifesciences Corporation · $52.34 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	58	16

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	1070	295
Atorvastatin Calcium	Atorvastatin Calcium	725	198
Rosuvastatin Calcium	Rosuvastatin Calcium	701	213
Levothyroxine Sodium	Levothyroxine Sodium	601	160
Amlodipine Besylate	Amlodipine Besylate	521	153
Metformin Hcl	Metformin Hcl	471	137
Pantoprazole Sodium	Pantoprazole Sodium	421	142
Lisinopril	Lisinopril	376	108
Metoprolol Succinate	Metoprolol Succinate	339	105
Tamsulosin Hcl	Tamsulosin Hcl	329	98
Carvedilol	Carvedilol	285	81
Gabapentin	Gabapentin	260	95
Diclofenac Sodium	Diclofenac Sodium	257	130
Eliquis	Apixaban	250	68
Alendronate Sodium	Alendronate Sodium	245	75
Omeprazole	Omeprazole	245	74
Azithromycin	Azithromycin	240	161
Hydrochlorothiazide	Hydrochlorothiazide	234	72
Escitalopram Oxalate	Escitalopram Oxalate	233	74
Glipizide	Glipizide	209	68
Chlorthalidone	Chlorthalidone	206	65
Alprazolam	Alprazolam	180	43
Simvastatin	Simvastatin	180	54
Furosemide	Furosemide	176	60
Albuterol Sulfate Hfa	Albuterol Sulfate	173	69
Levofloxacin	Levofloxacin	173	122
Tramadol Hcl	Tramadol Hcl	169	55
Donepezil Hcl	Donepezil Hcl	151	34
Trazodone Hcl	Trazodone Hcl	143	51
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	140	33
Atenolol	Atenolol	133	34
Fluticasone Propionate	Fluticasone Propionate	131	63
Baclofen	Baclofen	127	56
Zolpidem Tartrate	Zolpidem Tartrate	115	20
Famotidine	Famotidine	113	33
Lorazepam	Lorazepam	100	22
Clopidogrel	Clopidogrel Bisulfate	99	33
Valsartan	Valsartan	99	29
Potassium Chloride	Potassium Chloride	87	25
Ibuprofen	Ibuprofen	84	25
Montelukast Sodium	Montelukast Sodium	83	27
Januvia	Sitagliptin Phosphate	77	25
Allopurinol	Allopurinol	76	23
Metoprolol Tartrate	Metoprolol Tartrate	72	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	70	50
Finasteride	Finasteride	70	22
Ofloxacin	Ofloxacin	69	57
Celecoxib	Celecoxib	68	20
Temazepam	Temazepam	67	suppressed
Sertraline Hcl	Sertraline Hcl	66	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	65	20
Benazepril Hcl	Benazepril Hcl	63	15
Nifedipine Er	Nifedipine	63	15
Hydralazine Hcl	Hydralazine Hcl	62	16
Prednisone	Prednisone	61	28
Synthroid	Levothyroxine Sodium	58	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	57	15
Meclizine Hcl	Meclizine Hcl	56	36
Mirtazapine	Mirtazapine	54	20
Farxiga	Dapagliflozin Propanediol	52	13
Triamcinolone Acetonide	Triamcinolone Acetonide	52	33
Glimepiride	Glimepiride	51	13
Ondansetron Hcl	Ondansetron Hcl	50	31
Spironolactone	Spironolactone	49	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	47	11
Duloxetine Hcl	Duloxetine Hcl	45	15
Lansoprazole	Lansoprazole	44	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	42	27
Meloxicam	Meloxicam	42	19
Xarelto	Rivaroxaban	41	12
Cephalexin	Cephalexin	39	35
Lactulose	Lactulose	39	16
Metformin Hcl Er	Metformin Hcl	36	12
Amiodarone Hcl	Amiodarone Hcl	35	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Memantine Hcl	Memantine Hcl	35	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	34	34
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Ozempic	Semaglutide	32	suppressed
Sildenafil Citrate	Sildenafil Citrate	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Irbesartan	Irbesartan	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	11
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	31	12
Lovastatin	Lovastatin	30	suppressed
Latanoprost	Latanoprost	29	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	13
Nystatin	Nystatin	28	18
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Metronidazole	Metronidazole	27	18
Ezetimibe	Ezetimibe	26	suppressed
Telmisartan	Telmisartan	26	suppressed
Bupropion Xl	Bupropion Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	25	22
Glipizide Er	Glipizide	25	suppressed
Livalo	Pitavastatin Calcium	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Solifenacin Succinate	Solifenacin Succinate	24	suppressed
Jardiance	Empagliflozin	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Hydrocortisone	Hydrocortisone	21	11
Myrbetriq	Mirabegron	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Gemfibrozil	Gemfibrozil	20	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	20	suppressed
Cefuroxime	Cefuroxime Axetil	19	12
Fluconazole	Fluconazole	19	15
Pitavastatin Calcium	Pitavastatin Calcium	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	18	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Terbinafine Hcl	Terbinafine Hcl	18	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Mupirocin	Mupirocin	17	12
Terazosin Hcl	Terazosin Hcl	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Bupropion Hcl	Bupropion Hcl	16	suppressed
Diazepam	Diazepam	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	15	suppressed
Estradiol-Norethindrone Acetat	Estradiol/Norethindrone Acet	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Methimazole	Methimazole	14	suppressed
Carbamazepine	Carbamazepine	13	suppressed
Colchicine	Colchicine	13	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Mometasone Furoate	Mometasone Furoate	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Primidone	Primidone	12	suppressed
Repatha Sureclick	Evolocumab	12	suppressed
Repatha Syringe	Evolocumab	12	suppressed
Rivastigmine	Rivastigmine Tartrate	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Metolazone	Metolazone	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Scopolamine	Scopolamine	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed
Zaleplon	Zaleplon	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$177.33 · 2 records	ABBVIE INC.	RINVOQ, SAPIEN 3 Ultra RESILIA	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error